343 related articles for article (PubMed ID: 25268786)
1. Dopamine receptor activation increases HIV entry into primary human macrophages.
Gaskill PJ; Yano HH; Kalpana GV; Javitch JA; Berman JW
PLoS One; 2014; 9(9):e108232. PubMed ID: 25268786
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse.
Gaskill PJ; Calderon TM; Luers AJ; Eugenin EA; Javitch JA; Berman JW
Am J Pathol; 2009 Sep; 175(3):1148-59. PubMed ID: 19661443
[TBL] [Abstract][Full Text] [Related]
3. Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV.
Matt SM; Nickoloff-Bybel EA; Rong Y; Runner K; Johnson H; O'Connor MH; Haddad EK; Gaskill PJ
Front Immunol; 2021; 12():663061. PubMed ID: 34093554
[TBL] [Abstract][Full Text] [Related]
4. Human peritoneal macrophages from ascitic fluid can be infected by a broad range of HIV-1 isolates.
Chang TL; Klepper A; Ding J; Garber J; Rapista A; Mosoian A; Hubner W; Gutierrez J; Walewski J; Abergel J; Schiano T; Branch A
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):292-302. PubMed ID: 20065862
[TBL] [Abstract][Full Text] [Related]
5. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
6. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
7. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.
Tian Y; Zhang D; Zhan P; Liu X
Curr Top Med Chem; 2014; 14(13):1515-38. PubMed ID: 25159164
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
10. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
11. Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.
Yi Y; Loftin L; Wang L; Ratcliffe SJ; Isaacman-Beck J; Collman RG
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):285-92. PubMed ID: 18197116
[TBL] [Abstract][Full Text] [Related]
12. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
14. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
15. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.
Sterjovski J; Roche M; Churchill MJ; Ellett A; Farrugia W; Gray LR; Cowley D; Poumbourios P; Lee B; Wesselingh SL; Cunningham AL; Ramsland PA; Gorry PR
Virology; 2010 Sep; 404(2):269-78. PubMed ID: 20570309
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine enhances HIV infection of macrophages.
Liang H; Wang X; Chen H; Song L; Ye L; Wang SH; Wang YJ; Zhou L; Ho WZ
Am J Pathol; 2008 Jun; 172(6):1617-24. PubMed ID: 18458095
[TBL] [Abstract][Full Text] [Related]
17. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
18. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
19. Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway.
Nickoloff-Bybel EA; Mackie P; Runner K; Matt SM; Khoshbouei H; Gaskill PJ
Brain Behav Immun; 2019 Nov; 82():239-252. PubMed ID: 31470080
[TBL] [Abstract][Full Text] [Related]
20. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
